A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2008 New trial record.